흑색종

AntibodystaleBristol-Myers SquibbPhase 3

Nivolumab (BMS-936558, BMS-936558 (Nivolumab))

Melanoma · Melanoma

#Melanoma#Antibody#Phase3#항체#면역항체+2

효능 ORR 42.4%임상시험 1상태 ACTIVE

AntibodystaleM.D. Anderson Cancer CenterPhase 2

Relatlimab-Nivolumab FDC (BMS-986213, BMS-986213 (Relatlimab-Nivolumab FDC))

Melanoma (Skin) · Melanoma (Skin)

#MelanomaSkin#Antibody#Phase2#항체#면역항체+2

효능 ORR 61.9%임상시험 1상태 RECRUITING

AntibodystaleBiocon Biologics UK PLCPhase 1

Bmab1800 (Bmab1800)

Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings) · Adult Patients With Stage IIB, IIC, and

Nivolumab (BMS-936558, BMS-936558 (Nivolumab))

Relatlimab-Nivolumab FDC (BMS-986213, BMS-986213 (Relatlimab-Nivolumab FDC))

Bmab1800 (Bmab1800)

Cetuximab Dabrafenib Tislelizumab (Cetuximab Dabrafenib Tislelizumab)

Cetuximab Injection [Erbitux] (Cetuximab Injection [Erbitux])

nivolumab (Opdivo, Dose Escalation Doublet: Combination of NKTR-214 + nivolumab)

nivolumab (Opdivo, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab)

nivolumab (Opdivo, Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab)

ENV-501 (ENV-501)

nivolumab (Opdivo, EU-authorized Nivolumab)

Encorafenib Oral Capsule + Cetuximab (Encorafenib Oral Capsule + Cetuximab)

F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells (F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells)

nivolumab (Opdivo, FDA-licensed Nivolumab)

pembrolizumab (Keytruda, Fecal Microbiota Transplant with Pembrolizumab)

Part C (GM103 and Pembrolizumab, GM103 and Pembrolizumab (Part C))

nivolumab (Opdivo, IL-2 and Nivolumab)

ipilimumab and nivolumab (Immunotherapy, Immunotherapy (ipilimumab and nivolumab))

nivolumab and relatlimab (Immunotherapy, Immunotherapy (nivolumab and relatlimab))

Infliximab + Prednisone (Infliximab + Prednisone)

Ipilimumab IT (Ipilimumab IT)

흑색종

Nivolumab (BMS-936558, BMS-936558 (Nivolumab))

Relatlimab-Nivolumab FDC (BMS-986213, BMS-986213 (Relatlimab-Nivolumab FDC))

Bmab1800 (Bmab1800)

Cetuximab Dabrafenib Tislelizumab (Cetuximab Dabrafenib Tislelizumab)

Cetuximab Injection [Erbitux] (Cetuximab Injection [Erbitux])

nivolumab (Opdivo, Dose Escalation Doublet: Combination of NKTR-214 + nivolumab)

nivolumab (Opdivo, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab)

nivolumab (Opdivo, Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab)

ENV-501 (ENV-501)

nivolumab (Opdivo, EU-authorized Nivolumab)

Encorafenib Oral Capsule + Cetuximab (Encorafenib Oral Capsule + Cetuximab)

F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells (F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells)

nivolumab (Opdivo, FDA-licensed Nivolumab)

pembrolizumab (Keytruda, Fecal Microbiota Transplant with Pembrolizumab)

Part C (GM103 and Pembrolizumab, GM103 and Pembrolizumab (Part C))

nivolumab (Opdivo, IL-2 and Nivolumab)

ipilimumab and nivolumab (Immunotherapy, Immunotherapy (ipilimumab and nivolumab))

nivolumab and relatlimab (Immunotherapy, Immunotherapy (nivolumab and relatlimab))

Infliximab + Prednisone (Infliximab + Prednisone)

Ipilimumab IT (Ipilimumab IT)

흑색종

Nivolumab (BMS-936558, BMS-936558 (Nivolumab))

Relatlimab-Nivolumab FDC (BMS-986213, BMS-986213 (Relatlimab-Nivolumab FDC))

Bmab1800 (Bmab1800)

Cetuximab Dabrafenib Tislelizumab (Cetuximab Dabrafenib Tislelizumab)

Cetuximab Injection [Erbitux] (Cetuximab Injection [Erbitux])

nivolumab (Opdivo, Dose Escalation Doublet: Combination of NKTR-214 + nivolumab)

nivolumab (Opdivo, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab)

nivolumab (Opdivo, Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab)

ENV-501 (ENV-501)

nivolumab (Opdivo, EU-authorized Nivolumab)

Encorafenib Oral Capsule + Cetuximab (Encorafenib Oral Capsule + Cetuximab)

F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells (F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells)

nivolumab (Opdivo, FDA-licensed Nivolumab)

pembrolizumab (Keytruda, Fecal Microbiota Transplant with Pembrolizumab)

Part C (GM103 and Pembrolizumab, GM103 and Pembrolizumab (Part C))

nivolumab (Opdivo, IL-2 and Nivolumab)

ipilimumab and nivolumab (Immunotherapy, Immunotherapy (ipilimumab and nivolumab))

nivolumab and relatlimab (Immunotherapy, Immunotherapy (nivolumab and relatlimab))

Infliximab + Prednisone (Infliximab + Prednisone)

Ipilimumab IT (Ipilimumab IT)